ITP Foundation's
Guide to Understanding ITP

As a collaborative effort between Dr. Paul Imbach and the ITP Foundation, the ITP Foundation's Guide to Understanding ITP was developed to educate individuals diagnosed with ITP, their families, friends, and caregivers. Please download and familiarize yourself with our informative document.

ITPF logo
Click on the image above to view the PDF

About the Author
Dr. Paul Imbach is the Intercontinental Cooperative ITP Study Group (ICIS) Chairperson for the Hematology/Oncology Unit of University Children's Hospital in Basel, Switzerland. He is also the resident Medical Advisory Director for the ITP Foundation.

Library of Articles

The ITP Foundation receives numerous ITP related articles and is looking to stay current. We hope that the various articles provided for your reference in this section will help in your quest for more information about ITP. This information may potentially help you and your child's doctor devise an ITP management strategy. We would like to emphasize that information available from the resources above is for the purpose of reference only.

ITP Articles

Antibodies Redux - Platelet Antibody Testing Receives Tarnished Rep
Platelet antibody testing in patients with idiopathic thrombocytopenic purpura (ITP) has acquired a somewhat tarnished reputation. Measurements of platelet-associated immunoglobulin, while sufficiently sensitive to have a high negative predictive value, also carry a rate of false positive results so high as to be of no clinical use.

Anti-D Inhibits Erythrophagocytosis
Adult chronic immune thrombocytopenic purpura (ITP) is an autoimmune disorder manifested by thrombocytopenia from the effects of antiplatelet autoantibodies and Tlymphocyte–mediated platelet cytotoxicity. Multiple studies show that corticosteroid treatment and splenectomy, alone or together, increase platelet counts to safe levels in 60% to 70% of patients. However, there is little information on the outcomes of ITP patients refractory to splenectomy.

Biology & Treatment of ITP: What's Next??
Immune thrombocytopenic purpura (ITP) is the result of 2 pathologic processes: loss of tolerance to self-antigen accompanied by sustained autoantibody production, and antibody effector mechanisms that destroy platelets in excess of their production. There is a considerable challenge to hematologists treating the chronic, severe, refractory subset of patients. IVIG has many putative mechanisms of action in treating ITP.

Helicobacter Pylori in Children
Helicobacter pylori gastritis has been associated with autoimmune diseases, including idiopathic thrombocytopenic purpura (ITP).1,2 It is well known that the prevalence of H pylori infection is greatly variable from country to country, has decreased over the last decades in industrialized countries, and that its frequency increases with age. Recently, Veneri et al3 suggested that the HLA class II allele pattern might identify groups of ITP patients with different incidences of H pylori infection and, possibly, with different pathogeneses of thrombocytopenia.

ICIS Reports on ITP Activities

Study Shows No Adverse Reactions to Increased Infusion Rate of IVIG Treatment 2004.doc

Refractory Idiopathic Immune Thrombocytopenic Purpura in Children
Paul Imbach / University Children's Hospital, Bazel, Switzerland

Anti-D Initially Stimulates an Fc-dependent Leukocyte Oxidative Burst and Subsequently Suppresses Erythrophagocytosis via Interleukin-1 Receptor Antagonis

Malini D. Coopamah, John Freedman, and John W. Semple

Blood Disorder Doesn't Slow Down Princeton Youth
George Robinson / Kentucky New Era

Out for Blood: Maintaining a Supply of the Vital Fluid of Life Requires a Long Journey and Dedicated Work
Andrew Martel / The Winchester Star

Watchful Waiting for ITP?
RA Dershewitz Waiting ITP.Journal Watch.pdf

Short-Course, High Dose Steroids for ITP
Allan S. Brett, MD ITP.Journal Watch.pdf

Newly Diagnosed ITP -- Which Therapy is Best?
F. Bruder Stapleton, MD Diagnosed ITP.Journal Watch.pdf

Response to Intravenous Immunoglobulin Predicts Splenectomy Response in Children With Immune Thrombocytopenic Purpura
Derick Holt, Justin Brown, Kelly Terrill, Robert Goldsby, Rebecka L. Meyers, Jody Heximer, Beth Nordfors  and William B. Slayton Splenectomy Response.ITP.pdf

ITP: The Bad Actors
Alan Lichtin Splenectomy Bad actors.pdf

Immune Thrombocytopenic Purpura (ITP) Plasma and Purified ITP Monoclonal Autoantibodies Inhibit Megakaryocytopoiesis in Vitro
Mei Chang, Peggy A. Nakagawa, Shirley A. Williams, Michael R. Schwartz, Karen L. Imfeld, Jeffrey S. Buzby and Diane J. Nugent /  Children's       Hospital of Orange County Plasma.pdf

IVIG Induces Dose-Dependent Amelioration of ITP in Rodent Models
Andrew R. Crow, Seng Song, John W. Semple, John Freedman, and Alan H. Lazarus / St Michael's Hospital amlerioration.pdf

Helicobacter Pylori and Idiopathic Thrombocytopenic Purpura in Children
Jukka Rajantie and Timo Klemola / Helsinki University Central pylori in children.ITP.pdf

Helicobacter Pylori and ITP: Many Questions, Few Answers
Keith R. McCrae / Case Western Reserve University School of Medicine pylori.ITP.pdf

The Biology and Treatment of ITP: What's Next?
Steven E. McKenzie / Cardeza Foundation for Hematologic Research and treatment of ITP.pdf

Antibodies Redux
Douglas B. Cines / University of Pennsylvania Redux.pdf

Anti-CD40L: Biology and Therapy in ITP
Joseph Schwartz and James B. Bussel / New York Blood Center and Weill Medical College of Cornell University

Long-Term Outcomes in Adults with Chronic ITP After Splenectomy Failure
Robert McMillan and Carol Durette ITP Splenectomy Failures.pdf

donatenow logo

The ITP Foundation

facebook icon for column